We discover and develop novel TCR-based therapeutics against solid tumors
Our Science
We discover and develop a diverse, risk-balanced portfolio of novel TCRs against solid tumors leveraging our Deep Immunomics and Machine Learning platforms. In combination with novel tumor targets, ImmunoScape is using a multi-pronged approach to develop highly effective and differentiated T cell receptor based therapeutics.
Our Pipeline
ImmunoScape’s discovery engine is continuously generating unique TCR hits and is rapidly moving assets towards clinical candidate nomination. Our TCR-based therapeutics pipeline consists of different cell therapy programs against solid tumors.
Latest Articles
Our CEO and co-founder, Choon-Peng (Choon) Ng recently spoke with BioSpectrum Asia about how our...
ImmunoScape To Present at the 7th Annual CAR-TCR Summit San Diego, California and Singapore –...
ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell...
ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University....
About ImmunoScape
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies in the field of oncology. We are based in Singapore and in San Diego, US.